According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Heterogeneous safety profiles for dermatological and endocrine AEs
Not all GLP1-RA are the same
- Neuroendocrine tumors
Precision medicine in diagnostics and therapy
- Irritable Bowel Syndrome
Functional disorder of gut-brain interaction – a biopsychosocial concept
- GLP1 receptor agonists
Positive influence on substance use and addiction
- Sleep apnea and cardiovascular diseases
Breathless through the night
- Diagnostics, differentiation and multimodal therapy
Vulvar diseases and vulvodynia
- From symptom to diagnosis
Abdominal pain – Prostate lipoma
- Acute pulmonary embolism: new AHA/ACC guideline